Laurus Labs Announces Q2 Financial Results, Receives 'Hold' Rating from MarketsMOJO

Jul 25 2024 05:47 PM IST
share
Share Via
Laurus Labs, a leading pharmaceutical company, has announced its financial results for the quarter ending June 2024. Despite a decline in overall performance, the company has shown consistent growth in Dividend Payout Ratio. However, there are concerns regarding falling profits, debt management, and slower cash flow. Investors are advised to hold their positions and monitor future performance.

Laurus Labs, a leading pharmaceutical company in the largecap industry, has recently announced its financial results for the quarter ending June 2024. The company has received a 'Hold' rating from MarketsMOJO, indicating a neutral stance on its stock.

According to the financial report, Laurus Labs has seen a decline in its overall performance, with a score of -20 compared to -19 in the previous quarter. However, there are some positive aspects to note. The company has shown a consistent growth in its Dividend Payout Ratio (DPR) over the last five years, with the current ratio at 26.86%. This indicates that Laurus Labs is distributing a higher proportion of its profits as dividends to its shareholders.

On the other hand, there are some areas of concern for the company. The Profit Before Tax less Other Income (PBT) has fallen by 56.87% year on year, and the Profit After Tax (PAT) has also seen a decline of 49.7% year on year. The company's ability to manage interest payments has also deteriorated, with the Operating Profit to Interest ratio at its lowest in the last five quarters. Additionally, the company's operating cash flow has also decreased, indicating a decline in cash revenues from business operations.

The company's profitability has also taken a hit, with the lowest Earnings per Share (EPS) in the last five quarters. Laurus Labs has also increased its debt to fund its operations, with the Debt-Equity Ratio at its highest in the last five half-yearly periods. The company's pace of settling its debtors has also slowed down, with the Debtors Turnover Ratio at its lowest in the last five half-yearly periods.

Overall, Laurus Labs has shown a mixed performance in the quarter ending June 2024. While there are some positive aspects to note, the company also faces some challenges in terms of profitability and debt management. Investors are advised to hold their positions and monitor the company's performance in the upcoming quarters.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News